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Abstract
Radiotherapy is a local treatment modality employed in breast
cancer to reduce local recurrence following surgery. The observed
association of optimal local control with improved survival was not
expected in a disease characterized by early systemic spread. The
underlying mechanisms whereby the application of ionizing radiation
to the primary tumor site can have systemic effects remain unclear
and are the subject of much debate. In the present article we
discuss the hypothesis that radiotherapy has unique biological
effects and that, in addition to killing residual neoplastic cells after
surgery is performed, it might favorably alter the microenvironment
at the primary tumor site during the process of wound healing and
the development of antitumor immune responses.
Introduction
Local control by radiotherapy has been associated with
significantly improved breast cancer-specific survival.
The Early Breast Cancer Trialists meta-analysis of the data
available from 42,000 breast cancer patients who had
participated in 78 contemporary prospective randomized
trials (that had started after 1995) has provided invaluable
information on the relationship between local control and
patients’ overall and breast cancer-specific survival [1]. Over
a time span of 15 years, for every four local recurrences
avoided through optimal application of local treatment, one
death from breast cancer could be prevented – with the
consequent reduction on 15-year overall mortality. Noticeably
the proportional benefit derived by receiving radiotherapy was
detected in all patient subsets, independently of patient and
tumor characteristics or type of primary surgery (breast
conservation versus mastectomy).
This evidence has generated among the breast cancer
research community a new wave of reflection on the biology
of breast cancer and the effects of available treatment. An
example is Dr Punglia and coworkers’ editorial in the New
England Journal of Medicine, which engages in a compre-
hensive analysis to interpret the consequences of local
control on breast cancer survival [2]. These authors, however,
suggest that achieving optimization of systemic therapy will
eventually remove the benefit derived by adding radiotherapy
to the management of breast cancer.
We propose a different view, which attributes to radiotherapy
unique biological effects capable of directly and specifically
interfering with metastasis of breast cancer.
The fact that the benefit occurred only in the context of
successful local control suggests that events within the
irradiated field are implicated. Until recently, however, the
underlying mechanism of this connection remained elusive. A
commonly accepted hypothesis is that optimization of local
control, by adding radiotherapy to complement surgery, recruits
into cure a selected subset of patients who would have
otherwise recurred locally (failed surgery) and developed
subsequent metastases. This explanation implies a process
with distinct waves of cell migration and metastases with
differing invasive properties, influenced by events that occur
at the primary tumor site.
Metastases dissemination and colonization
The interpretation mentioned previously is consistent with the
emerging biological evidence that the metastatic process is
characterized by two distinct phases. The first phase, limited
to tumor cell dissemination to distant organs, consists of a
successful geographical migration of viable cells far away
from the primary tumor [3-5].
To enable migration, cancer cells of epithelial origin need to
acquire morphological and functional features identical to
those required to heal a wound – a process described as the
epithelial to mesenchymal transition (EMT) [6].
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A physiological component of wound repair, the process of
EMT is a stromal cell-driven mechanism that conveys motility
to epithelial cells to become invasive and permeate the
wound site in order to heal the gap created after surgical
removal. The same signaling transduction pathways of EMT
occur during gastrulation, at the beginning of embryogenesis,
when cells transfer from the neural crest of the ectoderm to
form the mesoderm, in preparation of mesenchymal tissues
for organogenesis. During EMT epithelial cells acquire both
the morphology and functional characteristic of fibroblasts.
Gene expression shifts from cytokeratins to vimentin, a
filament characteristic of the mesenchymal cytoskeleton,
while fibronectin, an extracellular matrix protein commonly
secreted by fibroblasts, is produced. E-cadherin production is
substituted by N-cadherin production, favoring motility of
cells [7].
The same complex cellular programs enabling cell migration
and invasion during gastrulation in embryogenesis and the
physiological repair of a wound are evoked in cancer meta-
stasis, suggesting that the pre-existing genetic program
underlying EMT in the cancer cell is strategically reactivated
at a crucial point in the natural history of cancer.
Preclinical data have shown that, despite the many chal-
lenges circulating tumor cells encounter, early distant dis-
semination is common even among invasive breast cancers
measuring less than 1 cm in diameter. This process results in
micro-metastatic, self-contained foci of cancer cells that
persist clinically silent in multiple organs until one of these
clusters acquires the necessary properties to establish
invasive, colonizing growth, to become a detectable meta-
static site and to re-disseminate systemically with a second
wave of micro-metastasis. Genetic analysis experiments
suggest that the latter step, colonization, is a more selective
one, and it is likely to be the step that drives cancer-specific
mortality [8].
In this model, the benefit from optimal local control is either
derived from interfering with the phase of dissemination, from
interfering with that of colonization, or from interfering with
both phases. To this end, several rapidly emerging lines of
evidence are shedding some light on what until now has
consistently eluded a biological explanation.
The surgical cavity as the site for EMT
Crucial biological effects associated with surgery at the
tumor site might impact on breast cancer systemic
recurrence. In a recent clinical study of patients with
HER2neu overexpressing tumors requiring re-excision to
assure negative margins, cell proliferation of the re-excised
specimen was higher than that of the original tumor. Besides,
fluid harvested from axillary drainage stimulated HER2-
positive mammary carcinoma cell growth in a two-dimen-
sional growth assay. The effect was abrogated by pretreat-
ment with trastuzumab, suggesting a role for HER2neu in the
inflammatory microenvironment that stimulates cell growth at
the wound site [9,10].
The original evidence that surgery modifies the kinetics of
breast cancer micro-metastasis [11,12] has been recently
corroborated by the increasingly recognized analogies of
EMT in wound repair and the acquisition of colonization
features. At the site of lumpectomy the physiological wound
repair process stimulates EMT for the breast tissue to heal.
EMT conveys motility to the epithelial cells on the periphery
of the cavity to become invasive and move towards the core
of the wound to heal the breast after surgical removal.
During this phase any residual neoplastic cell at the excision
site is also exposed to the physiological signaling associated
with inflammation and wound repair. This exposure could
conceivably enable neoplastic cells to acquire the tools for
EMT, harnessing them to display a more malignant,
colonizing behavior.
Evidence in support of this possibility emerged from the work
of Nuyten and colleagues, who compared three previously
established gene expression profiles of tumor tissue to
assess their predictive value for local recurrence after breast-
conserving surgery [13]. The 70-gene prognosis profile, the
hypoxia-induced profile and the wound-response signature
were tested in a cohort of 161 patients. At supervised
analysis the wound response signature was the only profile
with the ability to predict local recurrence: an activated
wound pattern versus a nonactivated wound pattern was
associated with an increased local recurrence rate. When
assessed in a Cox regression model that included classical
risk factors for local recurrence (age, tumor diameter and
radiotherapy dose to the tumor cavity), the supervised wound
response signature added significant prognostic information
at multivariable analysis (hazard ratio = 16, 95% confidence
interval = 1.9 to 125, P = 0.01) [13].
It is also conceivable that breast cancer patients undergoing
wound repair at the tumor cavity site generated by surgical
excision of the primary tumor could experience a wave of
metastatic reseeding/colonization. Interestingly, evidence
exists that breast cancer wound complications are associated
with an increased risk of systemic recurrence of breast
cancer [14].
Postoperative radiotherapy may act by eliminating residual
local tumor cells (at the original tumor bed, in the index
breast), including those that have undergone EMT changes
induced by the microenvironment of wound repair. Other
effects of radiotherapy could result in preventing or reducing
colonization after EMT. A recent study compared the
functional and proteomic characteristics of fluid obtained
from the breast cancer patients’ post-excisional cavities. The
day after surgery, fluid from the wound drainage was
collected and compared with preoperative plasma in two
separate groups of women who had undergone eitherPage 3 of 7
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surgery alone or had also received one intraoperative dose of
radiotherapy (20 Gy) [15].
When cocultured with breast cancer cell lines, the fluid from the
wound drainage stimulated proliferation, migration, and invasion.
Cell motility was assessed by chemotaxis and standard
Matrigel invasion assay, and by video time-lapse microscopy
of cells included in three-dimensional collagen I. The observed
effect was abrogated when the fluid from the wound drainage
tested was obtained from patients who had also undergone
intraoperative radiotherapy. On proteomic analysis, a distinct
profile of cytokine expression characterized irradiated versus
nonirradiated fluid from the wound drainage. The authors
proposed the concept that intraoperative radiotherapy could
have an additional series of effects other than classical cell
killing, by abrogating some of the detrimental consequences
associated with the formation of a surgical wound.
The tumor site as an immunogenic hub
An important actor at the tumor site is the immune system.
Tumor occurrence when recognized by clinical detection is
the obvious consequence of failed immune recognition and
rejection. Nevertheless, the immune system remains actively
involved in every step of cancer progression, including during
the phase of dormancy; for instance, CD8+ T cells maintain
the dormant status in preclinical cancer models [16]. More-
over, breast cancer patients with cytokeratin-positive cells in
the bone marrow also have an associated infiltration of
memory T cells [17].
A common mechanism tumors utilize to avoid rejection
consists of altering their phenotype to evade immunity, a
process defined as immunoediting [18]. Loss of specific
antigens or other important recognition molecules occurs
during tumor progression and after immunotherapy. Recent
data suggest that EMT could be the result of reprogramming
in response to immunological pressure [19]. When a tumor
cell line generated from a spontaneous tumor of the neu-
transgenic mouse and expressing the rat neu antigen was
injected into nontransgenic mice it was initially rejected by
the immune system. Over time, however, neu antigen-loss cell
variants that escaped recognition by the immune system
emerged. These tumor epithelial cells were found to display
morphological features of EMT, were found at microarray
analysis to show upregulation of invasion factors, and were
demonstrated to have acquired functional invasiveness when
tested in an in vitro migration assay. This work provides
preclinical evidence that an immune-mediated mechanism
could be at the origin of EMT in cancer [19].
Another immune-mediated mechanism shown to enhance
tumor progression is mediated by macrophages [20]. Infiltra-
tion of the tumor by tumor-associated macrophages corre-
lates with poor prognosis in breast cancer patients [10,21]. A
better understanding of this process will enable novel anti-
cancer applications.
Effect of local ionizing radiation on the
immunogenic hub
Important effects of ionizing radiation govern tumor
immunogenicity. Radiotherapy-induced cell killing is a form of
cell death effectively sensed by the immune system that
contributes important elements necessary to recover/induce
tumor-specific immunity potentially capable of rejecting the
colonizing clonogenic cells.
Our group has tested in the laboratory the hypothesis that
radiation-induced cell death and related danger signals are
sensed by the immune system and might contribute to the
global success of therapy [22-27]. The generation of this
hypothesis came from the clinical experience of testing con-
current chemoradiation in patients with locally advanced
breast cancer [28-30]. Characterized by already large, locally
advanced tumors at the time of initial diagnosis, these
patients rarely have detectable metastatic disease. Neverthe-
less, if left untreated most patients with locally advanced
breast cancer die of metastatic progression in 5 years,
suggesting a high metastatic potential.
To address the clinical challenge of tumors that often involved
the entire breast and were defined inoperable we originally
tested a preoperative treatment to enable surgical removal
with a negative margin, without the use of a skin flap to close
the wound. A moderate dose of local radiotherapy to the
involved breast and regional nodes (50 Gy in 28 fractions)
was delivered during continuous-infusion 5-fluorouracil chemo-
therapy. In a pilot trial of 35 originally inoperable women the
combined regimen enabled mastectomy with negative
margins in all patients [28,29]. A pathological response
(defined as disappearance of invasive disease or a limited
residual of <10 microscopic cancer foci) was achieved in
one-third of patients and resulted in a 72% disease-free
survival rate at 5 years – an unexpectedly high rate after a very
well tolerated approach – with light systemic therapy [31].
This unexpected success made us consider the possibility
that cell death induced by combined therapy might have a
systemic effect, and may reduce/delay the clinical expression
of micro-metastasis. The immune system appeared the best
candidate to contribute to the success encountered.
Multiple lines of evidence supporting this research direction
have since emerged. A series of preclinical studies designed
to test whether local tumor irradiation could promote sys-
temic tumor control was conducted. A mouse breast cancer
model in which tumor cells syngeneic to the recipient
immunocompetent mouse strain were implanted at two
separate sites demonstrated that irradiation of one tumor site
resulted in tumor growth inhibition at the other, nonirradiated,
site (abscopal effect) [22]. The administration of a growth
factor for dendritic cells was required in order for local tumor
irradiation to trigger the antitumor response, suggesting that
tumor cell death induced by radiation promoted the presen-
Available online http://breast-cancer-research.com/content/10/6/215tation of tumor-derived antigens by the dendritic cells, thus
acting to generate an in situ vaccine [22]. A similar require-
ment for boosting the number/function of dendritic cells,
which are often impaired in tumor-bearing hosts [32], was
shown by other workers in a lung cancer model in which a high
local radiation dose to the primary tumor was able to induce an
immune-mediated inhibition of the lung metastasis [33].
Further support for the concept that tumor cells killed by
radiation are a good source of antigens came from studies in
which, after exogenous dendritic cells were injected directly
into the irradiated tumor, a successful induction of antitumor
immunity was achieved [34,35]. More recently, the identifi-
cation of two of the molecular signals that determine the
immunogenicity of cancer cells killed by radiation – calreti-
culin and high-mobility group box 1 alarmin protein – has
provided the mechanistic proof that the irradiated tumor can
become an in situ vaccine [36,37].
To further translate these data to their clinical implications
(that is, to investigate the effect of local control by radio-
therapy on survival) we employed the 4T1 syngeneic mouse
model, which mimics the behavior of an invasive and meta-
static breast cancer and is characterized by early systemic
dissemination from the primary implantation site. Outgrowth
of lung metastases is usually responsible for death of the
animals. In this model, local tumor control by radiation was
associated with an improved survival only when an antitumor
immune response inhibiting metastases was induced, which
required administration of antibodies blocking the CTL-
associated antigen-4 receptor – an intervention that prevents
immune tolerance associated with suboptimal dendritic cell
function [25]. The results support the contention that the
effects of local radiotherapy on survival in the setting of
tumors with early dissemination are likely to depend on the
therapy’s ability to alter the tumor–host interactions and to
promote antitumor immunity.
Radiation and the microenvironment at the
immunogenic hub
With the improved understanding of the complexity of the
tumor microenvironment and its crucial role in regulating
tumor progression, the cells and extracellular components
that are altered by local radiotherapy are undergoing better
definition [38].
In addition to its cytocidal effects, ionizing radiation has
recently been shown to cause a plethora of changes on both
the cancer cells and tumor stroma, critical in determining its
therapeutic success. Many of these changes have been
proven in experimental systems to impact the ability of the
immune system to reject the tumor [27]. In addition to the
exposure of calreticulin and the release of high-mobility group
box 1 by dying cancer cells mentioned above, radiation also
induces the upregulation of cell surface and soluble
molecules that play important roles in mediating the
interaction of the tumor with the immune system. Radiation-
induced upregulation of Fas/CD95 and major histocom-
patibility complex class I molecules on cancer cells enhances
their recognition and elimination by antitumor T cells [39-41].
Similarly, upregulation of an adhesion molecule (VCAM,
vascular cell adhesion molecule 1) on tumor-associated
endothelia enhances the infiltration of the tumor by immune
cells [42].
We have recently shown that radiation markedly enhances
the release by human and mouse breast cancer cells of
CXCL16, a chemokine known to play an important role in
recruitment of effector T cells to sites of peripheral inflam-
mation (Figure 1). In the 4T1 mouse model, radiation-induced
CXCL16 release was critical for efficient recruitment of
antitumor T cells and tumor inhibition following treatment with
radiation and CTL-associated antigen 4 blockade [43]. The
modulation of chemokines by radiotherapy is thus another
mechanism by which the technique regulates the tumor
microenvironment and its relationship with the host immune
system.
Since success of standard anticancer therapies appears to
depend on recruiting contributing immune-mediated effects, a
synergy between immunotherapy and standard cancer
therapy needs to be pursued. On the other hand, some of the
local and systemic effects of radiotherapy have been shown
to enhance invasion and metastatic cancer progression [44].
Only clinical trials will provide support to the hypothesis that
immune mechanisms underlie the effect of local control on
systemic outcome.
Conclusion
Preclinical models of cancer generally fail to adequately
represent the complexity of human tumor–host interactions.
They have revealed, however, some of the potential mecha-
nisms that connect the achievement of radiation-induced
tumor control in the breast with an improved breast cancer-
specific survival. Preclinical evidence recapitulating the
results of the many interactions between radiotherapy and the
immune system has inspired ongoing clinical trials of radio-
therapy and immunotherapy.
On the other hand, a better understanding of the mechanism
of EMT and its implication in cancer metastasis offers an
opportunity for expanding the preliminary preclinical data of
ionizing radiation effects on residual cancer cells at the tumor
cavity.
Figure 2 summarizes the potential effects of ionizing radiation
on the surgical cavity, by interfering with EMT as well as with
the immune microenvironment at the site of the original tumor.
In conclusion, the existing clinical epidemiological evidence of
an association between local control and breast cancer-
specific survival has refocused the research community to
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From a radiation oncology point of view this is an invaluable
opportunity to elucidate novel mechanisms associated with the
effects of ionizing radiation, including its unexpected favorable
effects on the immune system, a central mediator of the
balance between cell survival and death. It is conceivable that
successful cooperation between breast cancer radiotherapy
and the immune system could result in sustained dormancy,
and might reflect on reduced cause-specific mortality.
The organism, after all, routinely refers to the immune system
to handle danger signals, with signal transduction pathways
that use the same receptors and ligands in response to virus,
bacteria or ionizing radiation [37].
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Figure 1
Enhanced expression of the chemokine CXCL16 following irradiation of human breast cancer cells. HTB20 cells, derived from a primary human
breast cancer [45], were harvested 48 hours after mock treatment (–) or after irradiation with a dose of 12 Gy (+) and a cell block was prepared as
previously described [46]. Sections (8 μm) were stained with H&E or with goat polyclonal antiserum against human CXCL16 (R&D Systems,
Minneapolis, MN, USA) or with normal goat serum as a control, followed by peroxidase-conjugated secondary antibody, were visualized with 3,3-
diaminobenzidine (DAB Substrate Kit; BD Pharmingen, San Diego, CA, USA), and were counterstained with hematoxylin. Magnification x400.
Figure 2
The surgical cavity and its microenvironment. (a) Process of epithelial to mesenchymal transition. (b) Digital radiograph of the lumpectomy cavity
targeted by a radiation boost field, limited by a multileaf collimator. Increased density characterizes the persistent fluid at the surgical wound site.
(c) Schematic representation of some of the effects radiation has on the immunological microenvironment of the tumor. DC, dendritic cell; ICAM,
intracellular adhesion molecule; MHC, major histocompatibility complex; RT, radiation therapy.References
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